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Abstract
Muscular dystrophy (MD) is the most common genetic lethal disorder in children. Mutations in
dystrophin trigger the most common form of MD, Duchenne and its allelic variant Becker MD.
Utrophin is the closest homologue and has been shown to compensate for the loss of dystrophin in
human disease animal models. However, the structural and functional similarities and differences
between utrophin and dystrophin are less understood. Both proteins interact with actin through
their N-terminal actin-binding domain (N-ABD). In this study, we examined the thermodynamic
stability and aggregation of utrophin N-ABD and compared with that of dystrophin. Our results
show that utrophin N-ABD has spectroscopic properties similar to dystrophin N-ABD. However,
utrophin N-ABD has decreased denaturant and thermal stability, unfolds faster, and is
correspondingly more susceptible to proteolysis, which might account for its decreased in-vivo
half-life compared to dystrophin. In addition, utrophin N-ABD aggregates to a lesser extent
compared with dystrophin N-ABD, contrary to the general behavior of proteins in which
decreased stability enhances protein aggregation. Despite these differences in stability and
aggregation, both proteins exhibit deleterious effects of mutations. When utrophin N-ABD
mutations analogous in position to the dystrophin disease-causing mutations were generated, they
behaved similarly to dystrophin mutants in terms of decreased stability and the formation of cross-
β aggregates, indicating a possible role for utrophin mutations in disease mechanisms.
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INTRODUCTION
Muscular dystrophy (MD) is a severe, debilitating group of neuromuscular diseases 2.
Duchenne (DMD) and Becker muscular dystrophies (BMD) account for more than half of
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all known MDs. These two diseases are caused by the loss of function of a vital muscle
protein dystrophin 3 whose gene resides on the human X-chromosome. These dystrophin-
related diseases physically weaken patients to a state of immobility, leading to death at an
early age. Dystrophin stabilizes the muscle cell membrane against the mechanical forces
associated with muscle stretch and contraction by connecting the actin filaments to the
sarcolemmal transmembrane glycoprotein complex 4–6. Mutations in dystrophin result in its
loss of function 7–12. Utrophin is a protein product of human chromosome 6 and is the
closest autosomal homologue of dystrophin 13–16. Utrophin has been shown to compensate
for the loss of functional dystrophin in human disease animal models 17–24. However, the
underlying physical mechanisms and the structural and functional similarities and
differences between utrophin and dystrophin are less understood.
Utrophin is confined specifically to the sarcolemma in fetal and regenerating muscle
cells 25–28. After down-regulation at birth, it is found predominantly at the myotendinous
and neuromuscular junctions in adult muscle cells to aid in optimal synapse transmission
and to play a stabilizing role at these junctions 16,29–32. Similar to dystrophin, utrophin is a
long, rod-shaped protein, and is made up of 3,433 amino acids (395 kDa). It has 60%
sequence similarity, and contains four distinct domains that are similar to dystrophin 6: an
N-terminal actin-binding domain (N-ABD) consisting of 261 residues, a central rod domain
consisting of 22 spectrin repeats and 4 hinge regions, a cysteine-rich (CR) domain and a C-
terminal (CT) domain. Utrophin interacts with actin using its N-ABD and the first 10
spectrin repeats in the central rod domain, and interacts with the sarcolemma glycoprotein
complex using its CR and CT domains6,16.
Considerable effort in recent years has been focused on understanding the functional and
biochemical differences between utrophin and dystrophin. Utrophin has been shown to
interact with dystrophin-associated proteins 33–36, and binds to actin similar to
dystrophin 35,37. However, clear marked differences exist between utrophin and dystrophin.
Utrophin interacts with actin through a different contact surface compared with
dystrophin 37, binds to lesser number of actin monomers 35,37, requires higher protein
concentrations to protect actin filaments against depolymerization 37, differentially affects
the structural dynamics of actin 38, and has a decreased in-vivo half-life 17,22,39,40. Some of
these functional and biochemical differences between dystrophin and utrophin, in particular
their in-vivo half-life, might originate from their differences in thermodynamic stability and
unfolding. Dystrophin and utrophin are two large proteins containing more than 3,400 amino
acids, and hence they are not amenable to many structural and biophysical methods that
measure protein stability and unfolding. Moreover, it is not yet possible to obtain high yields
of highly pure proteins necessary for biophysical studies. Therefore, we followed a
reductionist approach of studying individual domains, commonly used in protein structure-
function studies. In this study, we examined whether the N-ABDs of dystrophin and
utrophin differ in terms of their stability and unfolding. N-ABDs are of particular interest
because their crystal structures are known 41,42, and most disease-causing missense
mutations that trigger MD occur in the N-ABD of dystrophin 43,44.
Studying the stability of N-ABDs is also relevant in terms of improving the stability and in-
vivo half-life of the products of potential compensatory gene constructs such as utrophin
itself, and mini- and micro-dystrophins and utrophins. Such constructs have been shown to
compensate the loss of functional dystrophin in human disease mouse
models 17,18,23,24,45–51, and hold a high promise for future therapeutics to treat MD
patients 20,49,52–56. However, the products of these genes tend to have decreased stability,
functionality, and decreased in-vivo half-life 17,22,39,40,57,58 compared to the full-length
dystrophin. All these proteins contain in common the N-ABD with which the proteins
interact with F-actin and the C-terminal domains with which the proteins interact with the
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glycoprotein complex. Therefore, one method of stabilizing the proteins might be to increase
the stability of the component domains, for example, that of N-ABDs. For this purpose, we
need to first understand the stability and unfolding of dystrophin and utrophin N-ABDs that
share a high sequence and structure similarity.
In addition, studying the stability of the N-ABDs might shed light onto the structural
diversity and plasticity of tandem-calponin-homology (CH) domains 59–64. Such a tandem
array forms a major class of actin binding domains in muscle proteins. Individual CH
domains share a high sequence and structural similarity, but differ in their mode of binding
to actin. Such functional differences might originate from their differences in stability which
might dictate the various dynamic conformations available for individual CH domains. This
paper examines the stability differences between the N-ABDs of dystrophin and utrophin,
which are tandem CH-domains and are known to bind to actin with different modes of
contact 37,41,42,65.
MATERIALS AND METHODS
Protein expression and purification
N-ABDs of human utrophin (residues 1–261) and dystrophin (residues 1–246, C10S,
C188S) cDNA were cloned into a pET28a (N-terminal His tag; Novagen) expression vector
using NdeI and HindIII restriction sites and transformed into DH5α (Invitrogen) by the heat
shock method. Three different mutants in utrophin N-ABD (L70R, A84D, and Y246N) were
constructed using the Quick Mutagenesis protocol (Stratagene). Plasmid sequences of N-
ABDs of dystrophin, utrophin, and its mutants were confirmed by DNA sequencing. These
expression vectors were transformed into BL21-DE3 by the heat shock method. Cells were
grown in 2 L Luria broth (LB) and protein expression was induced with 0.5 mM Isopropyl
β-D-thiogalactopyranoside (IPTG) at a cell density corresponding to an optical density of
0.6 and incubated for 5 hrs at 37°C. Cell pellet was harvested and used for protein
purification. For utrophin and dystrophin N-ABDs, the cell pellet was resuspended in 50
mM Tris, 200 mM NaCl, pH7.5, 1 mM phenylmethylsulfonyl fluoride (PMSF; protease
inhibitor) buffer and sonicated with the samples kept on ice. Lysed suspension was
centrifuged at 30,000 g at 4°C for 40 min. Clear supernatant was loaded onto a Ni Sepharose
Fast Flow column (GE Lifesciences) and bound protein was eluted with an imidazole
gradient. Purity of elutes was evaluated using reducing SDS-PAGE gel. Pure elutes were
pooled and dialyzed against PBS buffer (0.1 M NaH2PO4, 0.15 M NaCl, pH 7). In the case
of mutant purification, the post-sonication pellet containing inclusion bodies was washed
twice with 50 mM Tris, 1 mM PMSF, 0.2 M NaCl, 0.5 % Triton X-100, pH 7.5 and with
double-distilled water. The cell pellet was solubilized in 10 ml of solubilization buffer (8 M
urea, 0.2 M NaCl, 50 mM Tris, pH 7.5), and incubated at room temperature for 30 min.
Solubilized suspension was centrifuged at 30,000 g for 30 min at 15°C. Clear supernatant
was used for the Ni-affinity column and eluted with the imidazole gradient in the above
solubilization buffer. Purity of elutes was checked on reducing SDS-PAGE gel. Pure elutes
were pooled and dialyzed against PBS buffer (0.1 M NaH2PO4, 0.15 M NaCl, pH 7). Mutant
aggregates in the dialysate were washed with PBS and were used for further experiments.
For labeling utrophin N-ABD with 15N for heteronuclear NMR experiments, the cell pellet
from 2 L LB culture (optical density ~ 2) was resuspended in 1 L sterile minimal media (48
mM Na2HPO4, 22 mM KH2PO4, 8.5 mM NaCl, 18.6 mM 15NH4Cl, 2 mM MgSO4, 0.1 mM
CaCl2, 0.4 % glucose) and grown for 2 hrs at 37°C. Protein expression was induced with 0.5
mM IPTG and incubated for overnight. Labeled utrophin N-ABD was purified using Ni-
affinity column chromatography.
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Fluorescence and CD
Fluorescence spectra of native and unfolded states (in 8 M urea) of utrophin and dystrophin
N-ABDs (1 μM each in PBS buffer) were recorded by exciting the samples at 280 nm
(Fluoromax3, SPEX). CD spectra were recorded on an Applied Photophysics ChirascanPlus
spectrometer.
Mean residue ellipticity (MRE) of the proteins were calculated from the CD values in
millidegrees using the equation 66
(Eq. 1)
NMR experiments
Labeled protein (150 μM) was used for recording 2D 15N/1H TROSY-HSQC spectra on a
900 MHz Varian NMR spectrometer (Rocky Mountain NMR Facility). Data was processed
using NMR Pipe software 67. For T1 and T2 measurements, modified pulse sequences
available with the Varian Biopack were used. τc was calculated using the equation,
where νN is the 15N resonance frequency.
Chemical denaturant melts
Utrophin and dystrophin N-ABDs (1 μM) in PBS buffer were used to monitor changes in
the CD signal at 222 nm (ChirascanPlus spectrometer; Applied Photophysics, UK) and
protein fluorescence with excitation at 280 nm (PTI QuantaMaster Fluorometer) with
increasing urea (Nacalai Tesque, 35940-81) concentration. For this experiment, buffer
samples with varying urea concentration were initially prepared and the protein was added
from a stock solution. The samples were allowed to equilibrate for an hour. The data were
normalized from 0 to 1 and fit to a 2-state model 68,69 using the SigmaPlot software (Systat
Software Inc) to obtain the ΔG and m values. We confirmed that the samples have reached
equilibrium within an hour by recording the denaturant melt of 1 μM dystrophin N-ABD
equilibrated overnight and found no change in the ΔG and m values. To confirm the absence
of a dimer (Kd = 4 μM) suspected from earlier published X-ray study on dystrophin N-
ABD 42, we performed denaturant melts at two protein concentrations (1 and 10 μM) and
found no change (Supplementary Figure).
Thermal melts
For utrophin and dystrophin N-ABDs (1 μM each in PBS buffer), changes in the far-UV CD
signal at 222 nm (ChirascanPlus spectrometer, Applied Photophysics, UK) and protein
fluorescence with excitation at 280 nm (PTI QuantaMaster Fluorometer) were monitored as
a function of increasing temperature at a rate of 1°C/min. For mutants (~1 μM), the CD
signal was recorded at 208 nm. The data were fit to a 2-state equilibrium unfolding model by
using SigmaPlot software to determine the Tm values.
Stopped-flow
Unfolding kinetics of utrophin and dystrophin N-ABDs were monitored using an Applied
Photophysics stopped-flow assembly attached to a ChirascanPlus spectrometer. Native N-
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ABDs (10 μM each) were diluted 10 times into PBS buffer containing varying
concentrations of urea, and the changes in the CD signal at 222 nm and the total protein
fluorescence with excitation at 280 nm were recorded. An average of 20 traces was fit to
exponential functions using SigmaPlot to determine the rate constants. The equation used for
fitting the kinetic data to a multi-exponential function was
(Eq. 2)
where kn and an represent the rate constants and the corresponding signal amplitudes. In the
above equation, n = 2 for two-exponential and n = 3 for three-exponential functions. The
amplitude-weighted average rate constant was determined using the equation
(Eq. 3)
For monitoring aggregation kinetics, unfolded N-ABDs (100 μM, PBS buffer, 8 M urea)
were diluted 10 times into PBS buffer without denaturant using a stopped-flow mixer, and
the changes in the right-angle light scattering with 450 nm excitation were monitored. An
average of 10 traces was plotted using SigmaPlot. At the end of the reaction, the amount of
refolded proteins were estimated by centrifuging the solutions at 30,000 g for 1 hr at 4°C to
remove insoluble aggregates and using the molar extinction coefficients at 280 nm
calculated using the ExPASy program (http://ca.expasy.org/) (46,075/(M.cm) and 38,960/
(M.cm) for dystrophin and utrophin N-ABD respectively).
Protease assay
Proteins (30 μg in 20 μl) were digested with a non-specific protease proteinase K (PK) at
37°C. To obtain the extent of proteolysis of the two proteins, the concentration of PK was
varied from 0 to 100 ng and the reaction was carried out for 30 min. To obtain the kinetics
of proteolysis of the two proteins, we fixed the PK concentration at 10 ng and the reaction
time was varied from 0 to 190 min. Digestion reaction was stopped by adding 20 μl of
reducing SDS-PAGE loading buffer. Samples were denatured by heating for 5 min at 100°C,
centrifuged at 20,000 g for 5 min, and the supernatant was loaded on the SDS-PAGE gel and
stained with Coomassie Blue. The intensity of the individual bands was determined using
the Quantity One software on Biorad Gel Doc XR+ instrument.
Dye-binding assays
Aggregates of utrophin N-ABD WT and mutants (2 μM aggregated protein) and 50 μM dye
concentration were used for dye-binding studies. Thioflavin T fluorescence spectra were
recorded using a Fluoromax3 fluorometer (SPEX) with 440 nm excitation. Congo red
absorption spectra were recorded using an Agilent spectrophotometer.
RESULTS
Amino acid sequence and structural comparison of utrophin and dystrophin N-ABDs
Compared with full-length proteins which have 60% sequence similarity 6, N-ABDs show
82% sequence similarity (Fig. 1A) when aligned using the ClustalW2 program 70
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Earlier X-ray crystal structures 41,42 indicate
that these domains contain two calponin-homology binding (CH) domains connected by an
Singh et al. Page 5
Proteins. Author manuscript; available in PMC 2013 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
α-helix (Fig. 1B). When aligned using the MultiProt program 71
(http://bioinfo3d.cs.tau.ac.il/MultiProt/), clear differences can be seen between the two N-
ABDs (Fig. 1C). The relative orientation of the two CH domains around the central α-helix
is distinctly different for the two N-ABDs, although the two CH domains of utrophin are
highly similar in structure to the corresponding CH domains from dystrophin (Fig. 1D).
Biophysical characterization of utrophin N-ABD
Similar to dystrophin N-ABD 43, we were able to obtain high yields of highly pure utrophin
N-ABD by expressing it in E. coli and purifying it using the metal affinity method (Fig. 2A).
Utrophin N-ABD consists of 261 residues, whereas dystrophin N-ABD has 246 residues;
hence, utrophin N-ABD appears as a slightly higher molecular weight band on the SDS-
PAGE gel (Fig. 2A). Utrophin N-ABD has similar spectroscopic characteristics to those of
dystrophin N-ABD. The circular dichroism (CD) spectrum shows two negative bands at 208
and 222 nm characteristic of an α-helical structure (Fig. 2B), consistent with its crystal
structure (Fig. 1B). In addition, the native fluorescence of utrophin N-ABD is blue shifted
with respect to its unfolded state (U) (Fig. 2C), similar to dystrophin N-ABD. The native
fluorescence emission maximum occurs at 334 nm and 338 nm for utrophin and dystrophin
N-ABDs respectively, whereas the unfolded state fluorescence maximum occurs at 355 nm
for both proteins. The blue shift in the tryptophan emission maximum of the native state
indicates the burial of tryptophan residues from the solvent 72. For tryptophans that are
exposed to solvent, this emission maximum occurs at around 355 nm, whereas for
tryptophans buried in the protein interior, the emission maximum occurs at around 325 nm.
The observed blue shift of 21 nm for utrophin N-ABD upon folding indicates that at least
some of the six conserved tryptophan residues are significantly buried in the protein interior,
implying that the protein has a well-folded structure.
Two-dimensional 15N-1H HSQC NMR spectrum (Fig. 2D) is consistent with the above
spectroscopic observations that the utrophin N-ABD has a well-folded structure in solution.
The crosspeaks between amide nitrogens and hydrogens are well-resolved on both 15N and
especially 1H chemical shift scale indicating that the individual nuclear spins experience
distinct structural environments in the protein, characteristic of a well-defined protein
structure. For an unfolded or molten-globule-like protein, amide crosspeaks will be in
general clustered in a single chemical shift region, in particular along the 1H chemical shift
scale. In addition, the average tumbling time or the rotational correlation time (τc) calculated
from the longitudinal (T1) and transverse (T 2) relaxation rates of individual amides indicate
that the protein is a monomer in solution (Fig. 2E). For a spherical protein with a similar
chain length to that of utrophin N-ABD, the expected correlation time is 17 ns 73, whereas
the experimentally measured correlation time was 19 ns. The slightly higher τc observed
suggests that the protein might be somewhat nonspherical. These NMR results in addition to
CD and fluorescence confirm that the utrophin N-ABD is a well-folded monomer in
solution, in agreement with the earlier structural and functional studies 31,34,41,65. Similar
results were observed for dystrophin N-ABD 43, which indicate that it is also a monomer in
solution.
Utrophin N-ABD is less stable than dystrophin N-ABD
Despite having high sequence and structural similarity to dystrophin N-ABD (Fig. 1),
utrophin N-ABD has a decreased thermodynamic stability (Figs. 3A–D). When protein
unfolding was measured using the chemical denaturant urea which destabilizes the native
protein structure, utrophin N-ABD unfolded at lower urea concentrations than did
dystrophin N-ABD (Figs. 3A & 3B). When CD at 222 nm was used to monitor the
unfolding of the secondary structure (α-helices) of the protein (Fig. 3A), utrophin N-ABD
consistently melted at 1.3 M [urea] units lower than that of dystrophin N-ABD. Fitting the
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melting curves to a 2-state equation 68,69 resulted in ΔG = 5.44 ± 0.30 kcal/mol and m =
−1.22 ± 0.06 kcal/mol/M [urea] for utrophin N-ABD, and ΔG = 9.81 ± 0.55 kcal/mol and m
= −1.68 ± 0.10 kcal/mol/M [urea] for dystrophin N-ABD (Table 1). These free energy
values indicate that utrophin N-ABD is less stable than dystrophin by 4.4 kcal/mol. In
addition, utrophin N-ABD has a lesser m-value compared to dystrophin N-ABD. The m-
value in denaturant melts is a measure of the amount of accessible surface area exposed
upon unfolding 74, which indicates that utrophin N-ABD might be less compact compared to
dystrophin N-ABD.
Similar results were obtained when protein fluorescence was used to monitor the unfolding
(Fig. 3B), which is often considered as a probe to measure unfolding of the tertiary structure
of a protein. Utrophin N-ABD consistently unfolded at 1.5 M [urea] units lower than
dystrophin N-ABD. The ΔG and m-values obtained by fitting these curves to a 2-state
equation 68,69 were ΔG = 7.79 ± 0.25 kcal/mol and m = −1.80 ± 0.06 kcal/mol/M [urea] for
utrophin N-ABD, and ΔG = 12.84 ± 0.77 kcal/mol and m = −2.23 ± 0.13 kcal/mol/M [urea]
for dystrophin N-ABD respectively (Table 1). These values indicate that the utrophin N-
ABD is less stable than dystrophin N-ABD by 5.1 kcal/mol when measured by fluorescence,
and the m-values indicate that utrophin N-ABD is less compact compared to dystrophin N-
ABD. These results qualitatively agree with the above conclusions drawn from CD
measurements (Fig. 3A). However, the ΔG and m values obtained from CD and
fluorescence measurements do not match, indicating that the two proteins do not follow a 2-
state unfolding mechanism. If a protein is a 2-state folder, i.e., there exists only native (N)
and unfolded (U) states with no partially unfolded intermediates, we expect to observe the
same ΔG and m values irrespective of the probe used to monitor unfolding. The
disagreement between the ΔG and m values measured by CD and fluorescence indicates that
partially unfolded intermediates do exist between the N and U states and populate at
equilibrium. Since the ΔG and m-values measured by fluorescence are higher than those
measured by CD, they might represent a close approximation of the true ΔG and m values
of the system.
Denaturant m values can be used to estimate the compactness of protein structure. As
described above, the m-value is proportional to the accessible surface area 74. X-ray crystal
structures of the two N-ABDs (Fig. 1B) were used to calculate the accessible surface area of
the native states (using the program Accelrys Discovery Studio Visualizer) as 13,311 Å2and
13,145 Å2 for utrophin and dystrophin N-ABDs respectively. Using the empirical equation,
urea m-value (cal/mol/M [urea]) = 374 + 0.11 (ΔASA) 74, we calculated the m-values as
−1.84 kcal/mol/M [urea] and −1.82 kcal/mol/M [urea] for utrophin and dystrophin N-ABDs
respectively. This estimated m-value for utrophin N-ABD closely matches with the −1.80
kcal/mol/M [urea] determined from urea melt measured by fluorescence (Table 1),
indicating that the conformation of utrophin N-ABD in solution might be similar to that in
the X-ray structure (Fig. 1B). However, the measured m-value (−2.23 kcal/mol/M [urea]) is
much higher than the estimated m-value (−1.82 kcal/mol/M [urea]) for dystrophin N-ABD,
implying that the solution state structure of dystrophin N-ABD might be much more
compact (by about 41%) than that in the X-ray crystal structure.
Temperature melts are commonly used in literature rather than chemical denaturant melts to
measure the thermodynamic stability of dystrophin and utrophin variants 43,44,57,75–77,
because the thermal melts require less protein (one protein sample) compared to the multiple
protein samples (prepared at different chemical denaturant concentrations) required for
denaturant melts. However, the results obtained from thermal melts have to be analyzed with
caution because these melts are not reversible, and should be interpreted on a qualitative
rather than on a quantitative scale. With temperature as the destabilizing agent and either CD
(Fig. 3C) or fluorescence (Fig. 3D) as the optical signal, utrophin N-ABD melted with a
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midpoint temperature (Tm) of 2°C less than that of dystrophin N-ABD (Table 1), indicating
that utrophin N-ABD is less stable than dystrophin N-ABD even at higher temperatures.
To confirm the absence of a dimeric form with a Kd of 4 μM suspected in earlier studies on
dystrophin N-ABD 42, we measured denaturant melts at two different protein concentrations
(Supplementary Figure). The melt recorded at 10 μM protein concentration exactly
overlapped with that recorded at 1 μM protein concentration, indicating the absence of
dimer under our experimental conditions. Consistently, all our experiments were performed
at native protein concentrations below 10 μM, except protein NMR (Figs. 2D & E).
Utrophin N-ABD unfolds faster than dystrophin N-ABD
The unfolding of N-ABDs was initiated by diluting the native proteins (10 μM) in the
absence of denaturant into a high denaturant buffer (8M urea) by 10 times using a stopped-
flow mixer. The kinetics was followed by measuring changes in the CD signal at 222 nm to
monitor the unfolding of the secondary structure (α-helices) of proteins (Figs. 4A & B).
These unfolding curves do not follow single exponential kinetics and were fitted to two
exponential function (Eq. 2) to obtain the unfolding rates. When monitored by CD, utrophin
N-ABD unfolded with two unfolding rate constants of 15.34 ± 0.60/s and 0.30 ± 0.02/s
(relative amplitudes of 43.8% and 56.2% respectively) (Fig. 4B and Table 1), whereas
dystrophin N-ABD unfolded with the rate constants of 2.81 ± 0.11/s and 0.13 ± 0.01/s
(relative amplitudes 44.1% and 55.9%) (Fig. 4A and Table 1). Comparing the individual rate
constants having similar amplitude, it is clear that the secondary structure of utrophin N-
ABD unfolds faster than that of dystrophin N-ABD. The unfolding experiment was repeated
at varying urea concentrations, and the changes in the unfolding rate constants with urea
concentration (unfolding chevron plot) was plotted in Fig. 4C. The measured rate constants
indicate that utrophin N-ABD consistently unfolded at a much faster rate compared to
dystrophin N-ABD at all urea concentrations.
When the same unfolding was monitored by protein fluorescence under identical conditions
(Figs. 4D & E), the unfolding kinetics of dystrophin and utrophin N-ABDs follow multi-
exponential kinetics, similar to when measured by CD (Figs. 4A–C). At 8 M urea, utrophin
N-ABD unfolds with two rate constants 10.38 ± 0.63/s and 0.36 ± 0.01/s (relative
amplitudes of 12.7% and 87.3% respectively) (Fig. 4E and Table 1), whereas dystrophin N-
ABD unfolds with three rate constants 32.84 ± 2.98/s, 1.65 ± 0.18/s, and 0.16 ± 0.01/s
(relative amplitudes of 8.6%, 12.0% and 79.4% respectively) (Fig. 4D and Table 1).
Comparing the rate constant with maximum amplitude (0.36/s vs. 0.16/s) or the amplitude
weighted average rate constant (0.41/s and 0.20/s for utrophin and dystrophin N-ABDs
respectively; Eq. 3 and Table 1), utrophin N-ABD unfolded faster than dystrophin N-ABD
by at least 2 times. The same phenomenon was observed when the experiment was
performed at varying denaturant concentrations. At all urea concentrations, utrophin N-ABD
unfolded faster than dystrophin N-ABD (Fig. 4F; compare red circles with black circles).
The slowest rate constant is always of the maximum amplitude in both N-ABDs when
measured by fluorescence and its amplitude qualitatively appears similar to an unfolding
melt (Fig. 3B). Hence, this rate constant might correspond to the population growth kinetics
of the unfolded state with increase in the denaturant concentration. Since dystrophin N-ABD
shows a 3-exponential unfolding kinetics, there exists at least two partially unfolded
intermediates between the native and unfolded states. For any kinetic system containing n
species, the maximum number of rate constants that can be observed will be n-1 78.
Similarly the two unfolding rate constants for utrophin N-ABD indicate that there exist at
least one intermediate between the N and U states.
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Utrophin N-ABD is more prone to proteolysis than dystrophin N-ABD
A nonspecific protease proteinase K (PK) was used to examine the proteolytic susceptibility
of the two proteins. In the first experiment (Figs. 5A & C), the two N-ABDs were subjected
to proteolysis at increasing concentration of PK for 30 min at 37°C. The band intensity
corresponding to the native utrophin N-ABD decreased with increasing protease
concentration at a faster rate compared with that of dystrophin N-ABD (comparing the
intensities of the bands inside the black boxes in Figs. 5A & C; plotted in Figs. 5B & 5D
respectively), indicating that utrophin N-ABD is more prone to proteolysis than dystrophin
N-ABD. The data were fitted to a single exponential function to estimate the effective
protease concentration that gave 50% degradation (PK50) 79 under the conditions used
(Table 1). The PK50 values were 11.9 ± 1.3 ng and 23.7 ± 2.6 ng for utrophin and dystrophin
N-ABDs respectively, which indicate that utrophin N-ABD requires less protease
concentration for its proteolysis compared to dystrophin N-ABD. In the second set of
experiments (Figs. 5E & G), the two proteins were subjected to proteolysis for varying
amounts of time at a fixed concentration (10 ng) of PK. With the increase in reaction time,
utrophin N-ABD band intensity decreased at a faster rate when compared with dystrophin
N-ABD (Figs. 5F & 5H). The rate constants obtained by fitting these kinetic data to a single
exponential function were 0.010 ± 0.002/min and 0.005 ± 0.001/min for utrophin and
dystrophin N-ABDs respectively. These rate constants indicate that utrophin N-ABD is
more prone to proteolysis compared to dystrophin N-ABD, consistent with the conclusions
drawn earlier (Figs. 5A–D).
The proteolysis pattern also differs between the two N-ABDs. At longer digestion times or
at higher protease concentrations, dystrophin N-ABD proteolyses into two smaller fragments
(Figs. 5A & 5E) whereas a major fraction of the utrophin N-ABD fragments exists as a
larger molecular weight fragment (Figs. 5C & 5G), which indicates inherent differences in
the stabilities of the local protein regions 80 between the two N-ABDs.
Utrophin N-ABD aggregates less than dystrophin N-ABD
No aggregation was seen for native utrophin N-ABD at room temperature, similar to
dystrophin N-ABD 43. Therefore, to monitor the aggregation propensity of these two
proteins, we unfolded the proteins using 8 M urea (100 μM protein concentration) and
initiated the aggregation reaction by diluting the denaturant 10 times in a stopped-flow
mixer. The kinetics was monitored by following the changes in right-angle light scattering at
450 nm where the proteins do not absorb. The increase in light scattering intensity is
proportional to the amount of protein aggregated. Dystrophin N-ABD aggregates at a much
faster rate compared to utrophin N-ABD (Fig. 6A). Both proteins showed typical nucleation
– propagation kinetics, with a longer lag time for utrophin N-ABD compared to dystrophin
N-ABD. These lag times which correspond to the formation of initial aggregation nuclei
indicate that the utrophin N-ABD has a lesser tendency to aggregate compared to dystrophin
N-ABD. At the end of the reaction, utrophin N-ABD refolded by about 24%, whereas
dystrophin N-ABD refolded by only 4% (Fig. 6B). These aggregation experiments indicate
that utrophin N-ABD aggregates to a lesser extent than does dystrophin N-ABD despite
having a lower stability.
Since the above aggregation reaction was initiated from the unfolded states, the aggregation
propensities of the two proteins might be dictated by the inherent properties of the amino
acid sequence rather than their thermodynamic stability. To exclude such possibility, we
used various computational programs 81,82 that predict the aggregation propensity of a
protein based on its amino acid sequence and found that there is no difference in the
aggregation propensity of the two polypeptide chains (Supplementary Table), which is
consistent with their high sequence similarity (82%) (Fig. 1A).
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Utrophin N-ABD mutants have decreased stability similar to that of dystrophin disease-
causing mutants
To determine whether utrophin mutations behave similar to disease-causing mutations in
dystrophin, we introduced three missense mutations L70R, A184D, and Y246N at analogous
positions to those of the dystrophin mutations, L54R, A168D, and Y231N. Like dystrophin
mutants 43, utrophin mutants aggregate significantly. When expressed in E. coli, the three
mutants were found only in inclusion bodies, in contrast to the wild-type (WT) utrophin N-
ABD which was predominantly expressed as a soluble protein (Fig. 7A). The three mutants
were purified by solubilizing inclusion bodies in 8 M urea and using Ni-affinity
chromatography (Fig. 7B). When the denaturant concentration was diluted, the mutants
aggregate by 99%. This behavior is similar to that of the disease-causing dystrophin
mutations 43. We used thioflavin T and congo red dyes to probe the structure of these
aggregates, which are two commonly used dyes that are known to bind to amyloid-like
cross-β structure 83,84. An increase in thioflavin T fluorescence and a red shift in congo red
absorption spectrum are two signatures of the cross-β structure in the protein aggregate.
Upon adding thioflavin T to preformed mutant aggregates, the dye fluorescence intensity
increased by on average 16 times compared with that in the buffer (Fig. 7C). This increase is
much higher than that observed for aggregates of the WT protein, indicating that the
mutations enhance the cross-β nature of the aggregates. Upon adding congo red to
preformed mutant aggregates, the dye absorption spectrum was red shifted on average by 70
nm (Fig. 7D). Similar to thioflavin T fluorescence, the observed red shift for mutant
aggregates is much higher than that observed for the WT protein aggregates. These two dye
binding assays indicate that the predominant structure in utrophin N-ABD mutant aggregates
is very similar to the cross-β structure observed earlier for dystrophin N-ABD aggregates 43.
Because most of the mutant proteins were expressed as inclusion bodies and purified under
denaturing conditions (8 M urea), it was difficult to obtain high quantities of soluble proteins
after refolding that were necessary to carry out urea melts. Hence, we used thermal melts to
measure the differences in their stability. We first confirmed that the urea unfolding and
refolding of the WT protein is reversible. The CD spectrum of the refolded WT exactly
overlaps with that of the freshly purified WT (Fig. 8A Top Panel). Also, refolded WT
melted with the same Tm as that of the freshly purified WT (Fig. 8B Top Panel). These
observations indicate that the utrophin N-ABD reaches the same authentic native
conformation after refolding from its denatured state at 8 M urea. In the case of refolded
mutants, L70R and A184D did not show a well-defined negative CD band at 222 nm
compared with the WT protein (Fig. 8A), indicating a decrease in their α-helical content.
The third mutant Y246N showed clear negative CD bands at 222 nm and 208 nm, similar to
the WT utrophin, suggesting that Y246N has a similar structure to the WT protein. We were
unable to calculate the mean residue ellipticity for mutants, as the soluble protein
concentrations we could obtain were less than 1 μM which were difficult to accurately
quantitate using either absorbance at 280 nm or micro-BCA assay. However, we could use
the ratio of CD at 222 nm to 208 nm to qualitatively determine the loss of native α-helical
structure. The ratios were 0.80, 0.75, and 0.93 for L70R, A184D, and Y246N mutants
respectively, whereas it was 0.94 for the WT protein. These values reconfirm that L70R and
A184D have decreased α-helical content whereas Y246N has an α-helical content similar to
that of the WT protein. The behavior of all three utrophin mutants is very similar to that
observed earlier for analogous mutations in dystrophin N-ABD 43, where L54R and A168D
mutants have decreased α-helicity whereas the Y231N mutant has a similar native structure
as that of the WT protein. In terms of thermal melts, the two mutants L70R and A184D did
not show a clear cooperative sigmoidal melt with the increase in solution temperature (Fig.
8B). The lack of a cooperative unfolding indicates the absence of a stable structure and that
the proteins probably exist in a ‘molten-globule’-like conformation. In contrast, the Y246N
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mutant showed a clear cooperative temperature melt indicating the presence of a stable
structure. However, its Tm is 7°C less than that observed for the WT utrophin N-ABD
indicating decreased stability of the mutant. These results indicate that the utrophin mutants
behave similar to dystrophin disease-causing mutants in terms of protein stability 43.
DISCUSSION
Utrophin expression is upregulated in MD patients and in dystrophin-deficient mdx mice;
however, it does not prevent the progressive muscle degeneration 16,27,32,85–88. Deletion of
utrophin in the mdx mouse that lacks dystrophin, the so called dystrophin-utrophin double
knockout dko mice, results in very severe symptoms of MD similar to those of human DMD
patients 89,90. This suggests that in mice and probably to some extent in humans, utrophin
does have some protective effect on muscle integrity. Expression of the utrophin gene in
muscles rescued the dko mice from MD symptoms and premature death 18,49. Additional
over-expression of utrophin using gene transfer methods rescued mdx mice from
MD 17,46,48. These ground-breaking animal experiments indicated that utrophin and
dystrophin might play synergistic roles in-vivo and that utrophin can compensate for the loss
of dystrophin. Therefore, a number of therapies have been proposed to increase utrophin
levels in muscles to treat MD patients 21,24,91. The main advantage of using utrophin is its
minimal immunological response because it is expressed at low levels even in those MD
patients who completely lack dystrophin 20,21,27,48,88,92. Despite the animal experiments and
proposed therapies, a complete understanding of how utrophin is similar to or different from
dystrophin in terms of protein structure and related biophysical properties is lacking, and
such an understanding will aid in designing better and more stable compensatory gene
products for therapeutic use.
Decreased in-vivo half-life of utrophin may result from its decreased stability
In recent studies, utrophin has been shown to interact with dystrophin-associated proteins
which include the sarcolemmal glycoprotein complex 33–36 and binds to actin with a similar
binding affinity to that of dystrophin 37, thus linking actin to the sarcolemma 35. However,
when dystrophin and utrophin DNAs were expressed in animal models using gene transfer
methods, dystrophin expression lasted longer compared with that of utrophin, indicating that
utrophin has a shorter half-life 17,22,39,40. One reason behind this difference may be because
of the decreased stability (Fig. 3) and faster unfolding (Fig. 4) of utrophin compared to
dystrophin. Decreased stability increases the non-functional unfolded state population at
equilibrium. Increased unfolding rate increases the transient population of the unfolded state
compared with the native state. Increased unfolded state population results in increased
protein degradation by proteasome and other proteases resulting in depletion of the
functional protein concentration, because the extent of proteolysis depends on the stability of
the substrate protein 80,93–96. Accordingly, less stable utrophin N-ABD is more prone to
proteolysis compared with dystrophin N-ABD (Fig. 5). A recently published study on the
full-length proteins 57 agrees with these inferences drawn based on the stability differences
of N-ABDs. In addition, a few other studies suggest the role of proteasome and proteases in
controlling the levels of dystrophin and utrophin in-vivo 97–99. Based on these results, one
possible method of designing stable utrophin constructs to compensate the functional
dystrophin loss seen in MD patients might be through increasing the stability of N-ABDs by
introducing stabilizing mutations, which might increase the in-vivo half-life of utrophin.
Utrophin may aggregate less than dystrophin
It has recently been shown that a possible physical mechanism by which missense mutations
in dystrophin trigger the disease is by inducing protein aggregation 43,44. In contrast,
utrophin possesses significant advantage over dystrophin in terms of protein aggregation.
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Starting from an unfolded state (analogous to a newly synthesized peptide by the ribosome
machinery), utrophin N-ABD aggregates to a lesser extent despite having a decreased
stability compared with dystrophin N-ABD (Fig. 6). This behavior contradicts the general
presumption in protein literature that less stable proteins aggregate to a higher extent 100–102.
We confirmed that the aggregation of the two proteins is not dictated by the primary
structure of the polypeptide chains.
One possible explanation for this behavior is that while refolding, dystrophin N-ABD might
misfold to a larger extent compared to utrophin N-ABD. The higher denaturant m-value for
dystrophin N-ABD indicates that it is more compact than utrophin N-ABD (Figs. 3A, 3B,
and Table 1), which might arise from the strength of the inter-CH-domain interactions in the
two proteins. In such a case, there will be a higher chance for incorrect docking of the two
CH domains during the folding of dystrophin N-ABD, which might result in increased
aggregation of dystrophin N-ABD compared to utrophin N-ABD.
Possible role of utrophin deficiency in disease mechanisms
Utrophin is the closest homologue of dystrophin, and is believed to function in a similar way
to dystrophin 6,35. Having high sequence, structural and functional similarity, it is highly
likely that mutations in utrophin behave similar to dystrophin mutations. It has been recently
shown that disease-causing mutations in dystrophin decrease its stability and lead to its
aggregation 43,44, resulting in decreased dystrophin levels seen in MD patients 103,104. Our
results presented here indicate that the utrophin mutations behave similar to dystrophin
mutations in terms of instability and aggregation, and therefore might lead to decreased
utrophin concentration in-vivo. Since utrophin expression is quite low in skeletal muscles in
the presence of dystrophin, decreased utrophin levels might not trigger MD. In the absence
of dystrophin, utrophin expression is upregulated 105, and hence any factors that diminish
the utrophin concentration might lead to the increased severity of disease progression.
Utrophin, being a large protein containing 3,433 residues and its gene containing 900
Kb 106, there will be a higher chance for the occurrence of sporadic mutations in-vivo
compared to proteins of smaller size, and any such mutations that decrease its stability might
make utrophin less effective in compensating the dystrophin loss. Alternatively, utrophin
mutations might affect muscle development in the fetus and/or affect synapse transmission
at myotendinous and neuromuscular junctions where utrophin plays a critical role. In
support, utrophin deficiency and its mutations have recently been implicated in diseases
such as myasthenia gravis, myelinopathies, cancer, and with those associated with the
central nervous system 107–112. Given the observation that utrophin is naturally upregulated
in DMD and mdx, it is likely to have a significant protective effect. Mutations in utrophin
that increase the instability of the protein could therefore be significant and detrimental
modifiers in DMD. Mutations in potential modifier genes such as utrophin, which to date are
unmapped, could contribute to the variation in phenotype and disease progression seen in
DMD patients.
Inter-CH-domain interactions might control the stability and aggregation of tandem-repeat
CH domains
Dystrophin and utrophin N-ABDs contain two CH domains linked by an α-helix (Fig. 1B).
Available X-ray crystal structures indicate that the orientation of CH domains around the
central α-helix might differ between the two proteins (Fig. 1C), although the structures of
individual CH domains are identical (Fig. 1D). Results from the denaturant melts (Figs. 3A
& 3B, and Table 1) indicate that utrophin N-ABD is less stable (lower ΔG) and has less
buried surface area (lower m-value) compared to dystrophin N-ABD, which might indicate
that the utrophin N-ABD has weaker inter-domain interactions. Consistently, recent results
on the solution conformation of utrophin N-ABD indicates that it is an open, extended
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conformation where the two CH domains are far apart 64. As discussed above, stronger
inter-CH-domain interactions in dystrophin N-ABD might explain why dystrophin N-ABD
aggregates to a higher extent compared to utrophin N-ABD because of the possibility of
incorrect docking of the two CH domains during folding. These observations suggest that
the stability, unfolding, and the aggregation behavior of tandem-CH-domains might be
controlled by the inter-domain interactions between the two CH domains.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We gratefully acknowledge the help from the Rocky Mountain 900 MHz NMR Facility (Funded by the NIH
instrumentation Grant P41GM068928) and Biophysics Core, University of Colorado Anschutz Medical Campus in
carrying out this work. We thank Javier Cabello-Villegas, Philip Reigan, Ruth Nussinov, Deborah Wuttke for
helpful discussions, and Walter Englander and John Carpenter for their critical reading of the manuscript. This
work was funded by the American Heart Association (to KMGM), a Jane and Charlie Butcher grant in Genomics
and Biotechnology (to KMGM), the ALSAM Foundation through the Skaggs Scholars Program (to KMGM), and
the Medical Research Council (to SJW).
Abbreviations
ABD actin-binding domain
BMD Becker MD
CD circular dichroism
CH domain calponin-homology domain
Cm midpoint denaturant concentration in chemical denaturant melt
DMD Duchenne MD
Dys dystrophin
ΔG Gibb’s free energy
HSQC heteronuclear single quantum coherence
Kd dimer dissociation constant
m-value the slope of ΔG variation with denaturant concentration
MD muscular dystrophy
MRE mean residue ellipticity
N native state
N-ABD N-terminal actin-binding domain
NMR nuclear magnetic resonance
PK proteinase K
Tm midpoint temperature in thermal melt
U unfolded state
Utr utrophin
WT wild-type
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Fig. 1.
Sequence and structural comparison of the N-ABDs. A. Amino acid sequence alignment of
the N-ABDs of human dystrophin (Dys; DMD gene product) and utrophin (Utr; UTRN gene
product) using the ClustalW2 program 70 (http://www.ebi.ac.uk/Tools/msa/clustalw2/).
Residues marked with an asterisk (‘*’) indicate identical residues and those marked with a
colon (‘:’) indicate highly conserved residues. Figure also shows the α-helix connecting the
two CH domains (red colored residues). B. X-ray crystal structures of dystrophin (Dys) and
utrophin (Utr) N-ABDs 41,42. C. Structural alignment of the N-ABDs using the MultiProt
program 71 (http://bioinfo3d.cs.tau.ac.il/MultiProt/). D. Structural alignment of the
corresponding CH1 (N-terminal) and CH2 (C-terminal) domains in the two N-ABDs using
the MultiProt program. In panels B – D, gray and red colored structures represent dystrophin
and utrophin N-ABDs respectively. Molecular structures were drawn using the program
Accelrys Discovery Studio Visualizer
(http://accelrys.com/products/discovery-studio/visualization-download.php).
Singh et al. Page 20
Proteins. Author manuscript; available in PMC 2013 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 2.
Biophysical characterization of the N-ABDs. A. SDS-PAGE of purified utrophin and
dystrophin N-ABDs. Lanes Dys and Utr correspond to dystrophin and utrophin N-ABDs
respectively. Lane M corresponds to the protein molecular weight markers (bottom to top:
11, 17, 26, 34, 43, 56, 72, 96, 130, and 170 kDa respectively). B. CD spectra of native
proteins. C. Fluorescence spectra of native (N) and unfolded (U) states. Black and red curves
in panels B and C correspond to dystrophin and utrophin N-ABDs respectively. D.
2D 15N-1H TROSY-HSQC NMR spectrum of utrophin N-ABD. E. T1, T2, and τc values for
individual amide crosspeaks of utrophin N-ABD (arbitrarily numbered, because the residue
assignments are not known at present). In this calculation, only strong and non-overlapping
peaks were considered.
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Fig. 3.
Protein stability measured using urea and temperature melts. A. Changes in the CD signal at
222 nm, and B. changes in the protein fluorescence with excitation at 280 nm as a function
of urea concentration. C. Changes in the CD signal at 222 nm, and D. changes in the protein
fluorescence with excitation at 280 nm as a function of increasing solution temperature. In
all the panels, black and red curves correspond to dystrophin (Dys) and utrophin (Utr) N-
ABDs respectively.
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Fig. 4.
Unfolding kinetics of the N-ABDs. Panels A & B show the unfolding kinetics in 8 M urea
when measured by CD signal at 222 nm. Panel C shows the variation in the unfolding rate
constants and their amplitudes with urea concentration. Panels D & E show the unfolding
kinetics in 8M urea when monitored by protein fluorescence. Panel F shows the variation in
the rate constants and respective amplitudes with urea concentration. In all panels, black and
red colored symbols represent the data corresponding to dystrophin (Dys) and utrophin (Utr)
N-ABDs respectively.
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Fig. 5.
SDS-PAGE of the N-ABDs digested with proteinase K. Panels A & B show the proteolysis
of dystrophin N-ABD whereas panels C & D show the proteolysis of utrophin N-ABD as a
function of increasing proteinase K concentration. The reaction was carried out at 37°C for
30 min. In panels B & D, circles and triangles represent two independent data sets. Panels E
& F show the proteolysis of dystrophin N-ABD whereas panels G & H show the proteolysis
of utrophin N-ABD as a function of increasing reaction time at 37°C and with 10 ng
proteinase K concentration. In all gel pictures, lane M corresponds to the protein molecular
weight markers (bottom to top: 11, 17, 26, 34, 43, 56, and 72 kDa respectively). For
obtaining the undigested fractions shown in panels B, D, F & H, the intensity of the band
corresponding to the native proteins inside the black colored boxes was used.
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Fig. 6.
A. Protein aggregation monitored by changes in the right-angle light scattering at 450 nm
initiated by diluting the denaturant 10 times starting from unfolded N-ABDs (100 μM; 8 M
urea). Black and gray curves correspond to dystrophin (Dys) and utrophin (Utr) N-ABDs
respectively. B. Refolding yields of dystrophin and utrophin N-ABDs.
Singh et al. Page 25
Proteins. Author manuscript; available in PMC 2013 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 7.
A. SDS-PAGE of WT utrophin N-ABD and its mutants expressed in E coli. S and IB
represent the protein content in solution phase and in inclusion bodies respectively. B. SDS-
PAGE of purified utrophin N-ABD mutants. In panels A and B, lane M corresponds to the
protein molecular weight markers (bottom to top: 11, 17, 26, 34, 43, 56, 72, 96, 130, and
170 kDa respectively). C. Increased thioflavin T (ThT) fluorescence when bound to protein
aggregates. The figure shows the fluorescence in buffer, in the presence of soluble native
WT protein (WT (N)), and when bound to aggregates (WT and mutants). D. Red shift in
congo red (CR) absorption spectra upon binding to protein aggregates. The figure shows the
spectra in buffer, in the presence of soluble native WT protein (WT (N)), and when bound to
aggregates (WT and mutants).
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Fig. 8.
A. CD spectra of WT utrophin N-ABD and its mutants refolded from their denatured states
at 8 M urea. B. Thermal melts of WT and mutants measured by CD at 222 nm recorded as a
function of increasing temperature. Top panels of A and B show the overlapping data of
freshly purified WT and refolded WT from its denatured state at 8 M urea.
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Table 1
Equilibrium and kinetic parameters obtained from protein melts (Fig. 3), unfolding kinetics (Fig. 4), and
protease assays (Fig. 5) of utrophin and dystrophin N-ABDs
Equilibrium/Kinetic parameter Utr N-ABD Dys N-ABD
Urea Melt (Figs. 3A & B)
CD (Fig. 3A)
 ΔG (kcal/mol) 5.44 ± 0.30 9.81 ± 0.55
 m (kcal/mol/M [urea]) −1.22 ± 0.06 −1.68 ± 0.10
Fluorescence (Fig. 3B)
 ΔG (kcal/mol) 7.79 ± 0.25 12.84 ± 0.77
 m (kcal/mol/M [urea]) −1.80 ± 0.06 −2.23 ± 0.13
Thermal melt (Figs. 3C & D)
 Tm (K) (CD; Fig. 3C) 332.1 ± 0.3 334.0 ± 0.1
 Tm (K) (Fluorescence; Fig. 3D) 333.3 ± 0.1 335.4 ± 0.1
Unfolding kinetics (Fig. 4)
CD (Figs. 4A–C)
 kn (/s) (Relative amplitudes) (8M urea) 15.34 ± 0.60 (43.8%)
0.30 ± 0.02 (56.2%)
2.81 ± 0.11 (44.1%)
0.13 ± 0.01 (55.9%)
 <k> (/s) (8M urea) 0.53 0.22
 mu (kcal.ln(/s)/mol/M [urea]) 0.31 ± 0.03
0.11 ± 0.01
0.28 ± 0.03
0.12 ± 0.02
Fluorescence (Figs. 4D–F)
 kn (/s) (Relative amplitudes) (8M urea) 10.38 ± 0.63 (12.7%)
0.36 ± 0.01 (87.3%)
32.84 ± 2.98 (8.6%)
1.65 ± 0.18 (12.0%)
0.16 ± 0.004 (79.4%)
 <k> (/s) (8M urea) 0.41 0.20
 mu (kcal.ln(/s)/mol/M [urea]) 0.24 ± 0.03
0.14 ± 0.02
0.06 ± 0.18
−0.07 ± 0.04
0.15 ± 0.02
Proteinase K assay (Fig. 5)
 PK50 (ng) (Figs. 5B & D) 11.9 ± 1.3 23.7 ± 2.6
 kproteolysis (/min/10 ng [PK]; Figs. 5F & H) 0.010 ± 0.002 0.005 ± 0.001
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